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Abstract: Objectives: This study is a retrospective investigation of the effects of repetitive botulinum
toxin A therapy (BoNT-A) and intensive rehabilitation (IR) on lower limb spasticity in post-stroke
patients. Methods: Thirty-five post-stroke patients was included in this study and received BoNT-A
for the first time. A 12-day inpatient protocol was with 4 cycles of the treatment protocol. The severity
of spasticity, motor function and brace status were evaluated. Results: The modified Ashworth
Scale (MAS) score of ankle dorsiflexors, range of motion, walking speed and balancing ability were
significantly improved after cycle 1. The improvement of spasticity and motor function was persistent
through cycles 2–4. One-third of brace users were able to discontinue the use of a brace. All of these
brace users showed a forward gait pattern prior to therapy. Conclusions: Repeated BoNT-A combined
with IR improved lower limb spasticity in post-stroke patients. Our results suggest that patients
who show the forward gait pattern prior to therapy may be able to discontinue the use of their brace
after therapy.
Keywords: botulinum toxin A therapy; stroke; rehabilitation
Key Contribution: The effect of repeated botulinum toxin A therapy and intensive rehabilitation.
1. Introduction
Botulinum toxins are produced by Clostridium botulinum bacteria and are the etiological agents
of botulism, a rare but severe disease for animals [1,2]. But, for their biological and toxicological
features, Botulinum toxins have become sophisticated tools to study neuronal physiology and valuable
therapeutics for an increasing number of human disorders [2]. Botulinum toxins have been classified
into seven different serotypes (from BoNT/A to /G). Type A have been clinically used for spasticity [3].
Botulinum toxin A therapy (BoNT-A) temporarily reduce muscle activity by preventing the release
of acetylcholine at the neuromuscular injection, resulting in reduced spasticity and muscle tone [4].
The effect of intramuscular injection of botulinum toxin type A pharmacologically commence 2–4 days
following injection, with the expected peak effect at 3 weeks [5]. Several open and placebo controlled
studies have reported the efficacy of local botulinum toxin injections in reducing spasticity and
empathizing its easy use and safety [6–11].
Post-stroke patients with hemiparesis may present with spasticity, a symptom of upper motor
neuron syndrome [12]. Spasticity is observed in 19% of patients at 3 months after stroke and 38% of
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patients at 12 months after stroke [13,14]. Spasticity can interfere with rehabilitation and the muscle
atrophy due to on-going spasticity, as well as the joint contractures and pain due to shortening of
muscle fibers and ligaments can prevent improvement of activities of daily living (ADL) and patient
reintegration into society [6]. Furthermore, lower limb spasticity limits the range of motion (ROM) of
the joint and the adjustment of muscle tone that are required for successful walking [7]. Lower limb
spasticity can result in the sustained over activity of the triceps surae muscle, which then leads to
equinus of the foot [15]. The equinus foot can cause ankle instability during the loading response
phase and poor toe clearance during the swing phase of gait [16]. Previous randomized controlled
trials (RCTs) indicated that BoNT-A reduces spasticity [8,9]. With regard to the lower limb, BoNT-A
injections have been reported to be effective for the improvement of pes varus and equinovarus foot,
reduction of clonus and improvement of walking velocity [15]. A systematic review of gait velocity in
RCTs reported a 0.044 m/s increase (an effect size of 0.193) in gait velocity in the treatment groups,
although the number of studies reporting such an improvement was small [17]. Therefore, more recent
studies have attempted the combined use of BoNT-A and rehabilitation to improve the motor function
of patients.
Previously, our study group implemented a combined treatment program of BoNT-A therapy with
multidisciplinary rehabilitation (MD-Re) and reported that this combined treatment was effective for
the improvement of motor function in post-stroke patients with upper and lower limb spasticity [18].
In addition, the effects of the combined treatment program varied depending on the extent of changes
in muscle fibers induced by sustained spasticity. Improvement of motor function was observed in
a case where muscle echo intensity was low but the improvement was poor in a case where muscle
echo intensity was high [19]. It has been known that the efficacy of BoNT-A attenuates in 3–4 months
after administration [6,7]. Therefore, the suppression of the development of persistent spasticity may
contribute to the maintenance and improvement of motor function in the long-term.
A previous study using the repeated administration of BoNT-A provided firm evidence for the
efficacy and safety of BoNT-A [10]. In addition, studies on post-stroke spasticity reported the persistent
effect of repeated administration of BoNT-A on spasticity and maintenance of patients’ functions [11,
20,21]. Only a few studies, however, have reported BoNT-A therapy for lower limb spasticity and
reports on the combined treatment with BoNT-A therapy and rehabilitation are further limited [22].
Therefore, we examined retrospectively the effect of the combined therapy of repeated BoNT-A
administration and rehabilitation to clarify whether the combined treatment improved spasticity,
whether the effect was maintained and whether it improved and maintained the motor function of the
lower limbs.
2. Results
2.1. Study Population Characteristic and Transition of BoNT-A Therapy
The study subjects included 35 patients and excluded 1 patient with post cerebral traumatic
spasticity. All patients completed 4 cycles of the inpatient treatment protocol. No patient postponed
the treatment due to the reduction of spasticity. No patient dropped out of or deviated from the
treatment cycle. Table 1 shows the characteristics of the patients in the current study. The patterns
of gait were classified into two types according to the relative positions between the affected and
unaffected feet in stepping the unaffected heel on the floor; forward or even. Table 2 shows the
relationship between the pattern of gait and the type of brace. The Gait Solution Design (Kawamura
Gishi Co., Ltd, Osaka, Japan) had the largest number of users [23,24]. The sites of injection and the
dosage are summarized in Table 3. In regard to the interval of injection, Cycle1-2, Cycle2-3 and Cycle3-4
were 18.1 ± 3.57 weeks, 16.2 ± 3.69 weeks and 15.7 ± 3.66 weeks, respectively and no significant
difference was observed.
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Table 1. Subject data.
All Patients
(n = 35)
Age at injection, years (SD) 60.6 (11.1)
Male / Female, n (%) 27 (77.1)/8 (22.9)
Type of stroke, n (%)
Cerebral infarction 13 (37.1)
Intracerebral hemorrhage 22 (62.9)
Side of hemiparesis
Rt/Lt, n (%) 17 (48.5)/18 (51.5)
Brunnstrom recovery stage, median (IQR)
Lower limb 4 (1)
Time between onset and treatment, months (SD) 47.0 (92.8)
Patterns of gait, n (%)
Forward: Wearing Brace/Not wearing 21 (80.7)/9 (19.3)
Even Wearing Brace/Not wearing 6 (66.6)/3 (33.4)
SD, standard deviation; Rt, right; Lt, left; IQR, interquartile range.
Table 2. The relationship between the pattern of gait and the type of brace.
Type of Brace
Forward Even
n = 21 (%) n = 6 (%)
Plastic ankle-foot orthosis 1 (4.8) 1 (16.6)
Ankle-foot orthosis with an oil
damper 7 (33.3) 0
Gait Solution Design 13 (61.9) 5 (83.4)
Table 3. Mean average injected dosage of botulinum toxin type A and the frequency of botulinum
toxin type A injection for each muscle.
Muscle, SD (%) Cycle 1 Cycle 2 Cycle 3 Cycle 4 p-Value
Total Upper Limb 148.2 ± 66.2 154 ± 62.6 132.9 ± 59.5 148.8 ± 59.5 n.s.
Subscapularis 1.57 ± 6.50 (5.7) 5.14 ± 10.4 (20.0) 11.57 ± 14.1 (42.8) 11.57 ± 14.1 (42.8)
Greater pectoral 12.7 ± 13.9 (45.7) 11.4 ± 16.4 (40.0) 8.71 ± 14.9 (28.5) 10.0 ± 16.2 (31.4)
Teres major 2.14 ± 7.10 (8.5) 3.57 ± 8.87 (14.2) 10.5 ± 14.5 (37.1) 9.28 ± 13.4 (34.2)
Biceps 26.5 ± 21.8 (68.5) 27.1 ± 18.5 (77.2) 19.4 ± 19.5 (57.1) 30.4 ± 27.4 (77.2)
Brachioradialis 2.85 ± 8.07 (11.4) 2.14 ± 7.10 (8.5) 0 (0) 0.7 ± 4.22 (2.8)
Flexor carpi radialis 19.4 ± 16.2 (65.8) 23.7 ± 14.8 (80.0) 16.2±18.8 (51.4) 22.6 ± 20.1 (65.0)
Flexor carpi ulnaris 13.0 ± 14.2 (48.5) 12.7 ± 12.5 (51.4) 11.4 ± 15.2 (40.0) 5.8 ± 10.9 (22.8)
Flexor digitorum
superficialis 36.1 ± 23.0 (85.7) 35.0 ± 18.9 (85.7) 28.1 ± 21.6 (71.4) 32.4 ± 21.6 (80.0)
Flexor digitorum
profundus 16.0 ± 17.5 (54.2) 14.4 ± 14.0 (54.2) 19.3 ± 17.7 (62.8) 14.6 ± 14.6 (54.2)
Flexor pollicis longus 9.21 ± 12.5 (37.1) 8.21 ± 11.7 (34.2) 1.78 ± 6.17 (8.5) 7.14 ± 11.4 (28.5)
Adductor muscle of
thumb 2.0 ± 6.66 (8.5) 2.92 ± 7.58 (14.2) 2.14 ± 7.10 (8.5) 1.42 ± 5.88 (5.7)
Lumbricales 2.35 ± 6.88 (11.4) 3.28 ± 8.30 (14.2) 0 (0) 2.14 ± 7.10 (8.5)
Total Lower limb 197 ± 55.4 192.5 ± 59.4 221 ± 55.7 205.4 ± 57.4 n.s.
Hamstring 6.42 ± 14.0 (20.0) 8.71 ± 20.2 (22.8) 11.5 ± 20.5 (28.5) 8.71 ± 14.9 (28.5)
Rectus femoris 9.0 ± 20.5 (20.0) 15.7 ± 25.0 (34.2) 20.4 ± 25.2 (45.7) 14.1 ± 24.1 (31.4)
Tibialis anterior 26.0 ± 23.5(74.3) 17.4 ± 17.0(60.0) 17.3 ± 20.4(54.2) 11.7 ± 17.7(34.2)
Tibialis posterior 37.5 ± 21.7(94.1) 27.4 ± 15.7(82.8) 36.4 ± 23.3(85.7) 37.6 ± 22.3(82.8)
Flexor hallucis longus 6.85 ± 11.1 (28.5) 13.8 ± 16.2 (45.7) 21.0 ± 19.9 (62.8) 19.5 ± 17.3 (62.8)
Flexor digitorum longus 4.71 ± 10.7 (17.1) 8.71 ± 12.4 (34.2) 12.1 ± 15.3 (42.8) 9.28 ± 14.9 (31.4)
Gastrocnemius 62.0 ± 30.1 (97.1) 60.0 ± 28.4 (97.1) 59.7 ± 24.9 (94.2) 65.2 ± 30.9 (94.2)
Soleus 37.7 ± 18.9 (91.4) 36.4 ± 15.6 (94.2) 35.1 ± 25.4 (77.1) 34.1 ± 24.8 (80.0)
Total 344.7 ± 26.3 346.5 ± 34.8 352.4 ± 19.5 351.4 ± 21.5 n.s.
SD, standard deviation. % indicates the injection frequency of patients in each group.
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2.2. Effect of Repeated BoNT-A Therapy Combined with Intensive Rehabilitation
Table 4 shows the changes in the assessment parameters in the 4 inpatient treatment cycles
compared with the parameters before the intervention. Regarding the upper limbs, MAS scores for the
shoulder, elbow, wrist and finger improved after Cycle 1 (Cycle 1 post) compared to the baseline values
and the improvements persisted until after Cycle 4 (Cycle 4 post) (p < 0.05). Similarly, FMA scores
also improved compared to the baseline values and the improvements persisted until after Cycle 4
(Cycle 4 post) (p < 0.05). As for the lower limbs, the MAS score for ankle dorsiflexors was significantly
improved after Cycle 1 (Cycle 1 post) and the improvement was persistent until after Cycle 4 (Cycle
4 post) (p < 0.05). Similar improvements and their persistence were observed in the range of motion
(ROM) at ankle dorsiflexion, 10-meter walking time (10MWT), functional reach test (FRT) scores and
the result of the timed up and go test (TUG) (p < 0.05).
Table 4. Change in assessment values.
Assessment
Cycle 1 Pre Cycle 1 Post Cycle 2 Post Cycle 3 Post Cycle 4 Post
Baseline
Brunnstrom recovery stage, median (IQR)
Upper limb 3 (1) 3 (1) 3 (1) 3 (1) 3 (1)
Finger 3 (1) 3 (1) 3 (1) 3 (1) 3 (1)
Lower limb 4 (1) 4 (1) 4 (1) 4 (1) 4 (1)
MAS, median (IQR)
Shoulder flexors 1.5 (1) 1 (0.5) * 1 (0.5) * 1 (0.5) * 1 (0) *
Elbow flexors 2 (0.5) 1.5 (0.5) * 1 (0.5) * 1.5 (0.5) * 1.5 (0.5) *
Wrist flexors 2 (0.5) 1 (0.5) * 1 (0.5) * 1 (0.5) * 1 (0.25) *
Finger flexors 2 (0.5) 1 (0.5) * 1 (0.5) * 1 (0.5) * 1 (0.5) *
Knee extension 1 (1.5) 1 (1) 1 (1) 1 (1) 1 (1)
Ankle dorsiflexors 2 (0.5) 1.5 (0.5) * 1.5 (0.5) * 1 (0.5) * 1 (0.5) *
ROM, angle, average (SD)
Hip flexion 109.6 (9.98) 111 (8.95) 109.6 (9.75) 110.6 (9.44) 112.1 (8.54)
Knee extension 132.5 (10.5) 135.1 (7.12) 130.0 (23.9) 133.8 (7.48) 133.4 (6.83)
Ankle dorsiflexion 4.85 (10.1) 11.5 (7.74) * 10.6 (6.83) * 10.0 (7.17) * 8.85 (6.42) *
FMA, Upper limb median (IQR) 14 (17) 16 (18) * 17 (18.5) * 19 (20) * 19 (18.5) *
10MWT, s, median (IQR) 26.9 (31.9) 23.2 (21.6) * 18.7 (22.4) * 19.8 (23.5) * 18.9 (17.1) *
FRT, cm, median (IQR) 15.5 (10.6) 22.5 (10.8) * 22.0 (7.0) * 22.0 (6.5) * 25.0 (11.0) *
TUG, s, median (IQR) 27.0 (31.5) 22.3 (21.9) * 22.1 (17.9) * 21.1 (21.7) * 20.2 (19.7) *
* Statistically significant difference between admission and discharge (p < 0.05). IQR, interquartile range. SD,
standard deviation. FMA, Fugl-Meyer Assessment.
Figure 1A shows the change in the use status of braces in patients. Some patients were able to
change their brace due to the improvement of spasticity and ROM of the ankle. In addition, one-third
of patients who initially wore a brace no longer needed the brace at the end of Cycle 4 (Cycle 4 post).
Regarding the relationship between gait pattern of the patients and their use status of braces at the end
of Cycle 4 (Cycle 4 post), the gait pattern of all of patients who came off of a brace (Brace-off group)
was the forward gait pattern (Figure 1B).
2.3. Comparison between Three Groups
The patients were classified into the following three groups: patients who did not wear a brace
throughout the study (Not wearing group); those who came off of a brace (Brace-off group); and those
who continued to use a brace (Brace-on group). The ROM of the ankle was significantly better in the
not wearing group and the brace off group than in the brace on group (p > 0.05) (Figure 2) but no
significant differences were observed in other parameters among the groups.
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3. Discussion
In the present study, we implemented a combined treatment program of repeated BoNT-A
therapy and rehabilitation for post-stroke patients with spasticity and examined its effect on spasticity,
motor function and the use of braces. Our results demonstrated an improvement of spasticity by
the combined treatment program and maintenance of the improvement. In addition, the combined
treatment enabled improved lower limb motor functions in the post-stroke patients and their brace
use status. This is the first report on the combined treatment program of repeated BoNT-A therapy
and intensive rehabilitation.
In this study, there was the high standard deviation in the age at injection and time between onset
and treatments. Several years have passed since BoNT-A therapy in Japan. Therefore, BoNT-A therapy
has become the available tool for spasticity in post-stroke patients. Thus, it was difficult to find patients
who had not been treated with BoNT-A therapy. And, compared with the subject date of clinical
trials in Japan, the average scores of the age at injection and time between onset and treatments were
similar [6,7]. In this study, the youngest patient was the 30s and the oldest patient was the 80s in years
of age. In the time between onset and treatments, one patient was 488 months and apart from this
patient, three patients were over 100 months. Therefore, it is thought that the number of cases affected
the standard deviation. There were more patients with a forward gait pattern than patients with an
even gait pattern. In addition, there were more patients who used a brace than patients who did not
use a brace prior to the intervention. Ankle-foot orthotic therapy for patients with post-stroke paresis
and spasticity not only prevents contracture and deformity of joints and mitigates spasticity but also
plays a pivotal role in regaining walking ability and relearning motor functions [25]. An ankle-foot
orthosis with an oil damper and Gait Solution Design is especially effective to promote the forward
driving force in the gait cycle by assisting heel rocker function [24]. The patients included in the
current study that used ankle-foot orthotic devices prior to the intervention were most likely to benefit
from these effects and we speculate that many of these patients attained the forward gait pattern as a
result. A previous study demonstrated that the combined use of BoNT-A injection and orthotic therapy
improved walking speed, increased peak ankle dorsiflexion during the stance phase and increased the
peak ankle plantarflexion moment during the swing phase [26]. The combined use of an orthosis with
BoNT-A therapy may have a substantial influence on the improvement of walking ability.
As for the changes in the total dose of BoNT-A and its injection site, the total dose of BoNT-A in a
cycle and the interval between cycles (weeks) did not change significantly. The most likely reason for
no significant changes in the interval between cycles was because the interval was set between 12 and
20 weeks in the treatment protocol. The total dose of BoNT-A in each cycle and its distribution into
individual muscles were decided at the time of medical examination for each cycle. We speculated that
the combined treatment with BoNT-A injection and intensive rehabilitation would reduce the total
dose of BoNT-A gradually through repeated treatment but the total dose remained rather constant.
On the other hand, with regard to the mean injected dosage of BoNT-A into individual muscles,
the distributions of BoNT-A into the tibialis posterior muscle, gastrocnemius muscle and soleus muscle
were constant, while the distribution into the tibialis anterior muscle decreased and the distributions
into the flexor hallucis longus muscle and flexor digitorum longus muscle increased during the current
study. This finding suggests that gradual improvement of varus and equinus conditions with repeated
treatment made it possible for the dose of BoNT to be distributed into other muscles. In the future,
it will be necessary to observe the long-term changes in the total dose and distribution to individual
muscles over a treatment course.
We demonstrated a significant reduction of MAS scores in the upper and lower limbs and the
maintained this reduction during the study period in the current treatment protocol. These results
are consistent with those in previous studies [11,20,21]. In the upper limb, improvement of upper
limb function, as well as the reduction of MAS scores were observed. A previous study demonstrated
that repeated treatment with BoNT-A improved upper limb function, as well as spasticity in patients
with post-stroke upper limb spasticity [27]. In addition, in relation to the improvement of lower
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limb function that will be discussed below, BoNT-A therapy on the upper limb may improve gait
disturbance since by improving balancing ability and walking speed [28,29]. The mitigation of upper
limb spasticity improves walking ability through the improvement of the position, swinging ability
and voluntary movement of the upper limb. In the lower limb, the combined treatment of BoNT-A
therapy and intensive rehabilitation not only improved MAS scores and the ROM of the ankle but also
improved motor function and balancing ability. These effects of the combined treatment persisted
throughout the study. A previous study reported an improvement of the MAS score of the ankle and
walking ability by the repeated administration of BoNT-A [22] and our present results supported those
findings. We speculate that the combined use of intensive rehabilitation and BoNT-A therapy creates
a favorable environment to improve motor function and spasticity through listening to the patient’s
needs at every treatment administration. Therefore, the combination therapy allowed adjustment of the
orthotic device or to have the patient stop using the device. Teasell et al. examined the rehabilitation
management of post-stroke patients and reported that proper management and training for spasticity
was effective for the improvement of motor function in post-stroke patients, even at 6 months or more
after onset [30]. The results of the present study support their findings.
All of the patients in the brace-off group showed the forward gait pattern. With regard to
the mechanism of improvement, the reconstruction of neuroplasticity and the relearning of motor
functions, the mechanism for acquisition of a normal pattern of motor function is very important.
Therapeutic intervention to induce patients’ relearning of such motor functions is also important.
Therefore, our results suggest that the combined treatment program contributed to the relearning of
motor functions. In addition, our results suggest the importance of leading patients to the forward
gait pattern in the post-stroke acute or subacute phase prior to the introduction of the treatment for
spasticity. Furthermore, it is important to examine the types of patients that can acquire the forward
gait pattern based on the type of stroke and the size of cerebral damage. A recent study examined the
therapeutic effect of BoNT-A for spasticity in the early phase after the onset of stroke and demonstrated
a significant reduction of MAS scores for the ankle [31]. Relearning and re-establishing walking
ability and balancing ability is important for rehabilitation in the early phase after the onset of stroke.
Therefore, the significance of a combined treatment using BoNT-A therapy and rehabilitation is clear
in regard to the suppression of spasticity and the learning of a proper gait pattern.
Lastly, there are several limitations to the present study. First, this was a retrospective study with
no control group. Ideally, we should have set an intensive rehabilitation only group or a BoNT-A
monotherapy group. Second, the number of cases included in the current study is small. Several years
have passed since BoNT-A therapy for post-stroke patients became widely available in Japan, thus,
it was difficult to find patients who had not been treated with BoNT-A therapy. Third, it is necessary
to follow patients who continued the use of a brace after the 4 cycles of treatment. In this study,
the patients were followed for 12 or 15 months with 4 cycles of treatment but it may be necessary to
observe their clinical course and the persistent effect of the treatment. In addition, there is a possibility
that the patients who no longer required a brace may require a brace in the future if their walking
ability decreases. Therefore, we will conduct a long-term follow-up of the patients on their clinical
course and continue the treatment in the future.
4. Conclusions
The combined treatment of repeated BoNT-A therapy and intensive rehabilitation for lower limb
spasticity in post-stroke patients mitigated spasticity and the effect was persistent throughout the
study. Our results indicate that the combined treatment is effective for the improvement of lower limb
motor function and the maintenance of the improvement. In addition, our results suggest that patients
who showed the forward gait pattern before starting the intervention may be able to stop using a brace
during or after treatment.
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5. Materials and Methods
5.1. Study Design
Figure 3 shows a flow chart of the study. Study subjects were patients introduced to BoNT-A
therapy for the first time during a period from April 2014 through January 2017. One treatment cycle
was defined as a 12-day inpatient treatment protocol including BoNT-A therapy, intensive rehabilitation
and assessment of motor function before and after the hospitalization. As for the interval between
BoNT-A injections, BoNT-A was injected again between 12 weeks to 20 weeks after the last injection.
The patients underwent 4 cycles of the inpatient treatment protocol. If the modified Ashworth scale
(MAS) score was 1 or below, the treatment was postponed.
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cerebral traumatic spasticity. 35 patients completed 4 cycles of the inpatient treatment protocol. One 
treatment cycle was defined as a 12-day inpatient treatment protocol. At admission, all patients' motor 
function before BoNT-A injections was evaluated. Beginning on the following day, the rehabilitation 
program was administered for 11 consecutive days. At the last day of this protocol, the motor function 
after intensive rehabilitation was evaluated for all patients. As for the interval between BoNT-A 
injections, BoNT-A was injected again between 12 weeks to 20 weeks after the last injection. 
Abbreviation: BoNT-A, botulinum toxin type A. 
5.2. Participants 
We conducted an investigation of patients who visited Kikyogahara Hospital for BoNT-A 
injections and inpatient rehabilitation. The following inclusion criteria were used: (1) patients with 
hemiplegia following a stroke that involved upper and lower limb spasticity, (2) MAS of the ankle 
score ≥ 2 at cycle 1, (3) >6 months since the onset of stroke, (4) no prior BoNT-A injections, (5) no 
contraindications for BoNT-A injections and (6) the patient desire of additional improvements of 
hemiplegia. The exclusion criteria were: (1) only an upper limb being appropriate for BoNT-A 
injections, (2) unable to walk without assistance, (3) taking anti-spasticity medications, (4) a history 
of BoNT-A injections, (5) a history of surgery for spasticity due to stroke and (6) severe cognitive 
impairment.  
The current study was compliant with the Declaration of Helsinki and written informed consent 
was obtained from all participants. The current study was conducted following approval from the 
institutional ethics committee of Jikei University School of Medicine and Kikyougahara Hospital. 
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Figure 3. The study design. The study subjects included 35 patients and excluded 1 patient
with. post cerebral traumatic spasticity. 35 patients completed 4 cycles of the inpatient treatment
protocol. One treatment cycle was defined as a 12-day inpatient treatment protocol. At admission,
all patients’ motor fu ction before BoNT-A injections was evaluated. Beginning on the following day,
the rehab litation program was administer r 11 consecutive days. At the ast day of this protocol,
the motor function after intensive rehabilitatio was evaluated for all patients. A for the interval
between BoNT-A injections, BoNT-A was injected again between 12 weeks to 20 weeks after the last
injection. Abbreviation: BoNT-A, botulinum toxin type A.
5.2. Participants
We conducted an investigation of patients who visited Kikyogahara Hospital for BoNT-A
injecti ns and inpatient rehabilitatio . The following inclusi n criteria were used: (1 patients
with hem plegia foll wing a stroke that involved upper and l wer limb spasticity, (2) MAS of
the ankle score ≥2 at cycle 1, (3) >6 months since the onset of stroke, (4) no prior BoNT-A
injections, (5) no contraindications for BoNT-A injections and (6) the patient desire of additional
improvements of hemiplegia. The exclusion criteria were: (1) only an upper limb being appropriate
for BoNT-A injections, (2) unable to walk without assistance, (3) taking anti-spasticity medications,
(4) a history of BoNT-A injections, (5) a history of surgery for spasticity due to stroke and (6) severe
cognitive impairment.
The current study was compliant with the Declaration of Helsinki and written informed consent
was obtained from all participants. The current study was conducted following approval from the
institutional ethics committee of Jikei University School of Medicine and Kikyougahara Hospital.
This study was registered with the University Hospital Medical Information Network Clinical Trials
Registry (UMIN-CTR) (UMIN 000033463).
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5.3. Procedures
BoNT-A was administered based on the guidelines of Sheean et al. [32]. The maximum doses
for the upper limb, lower limb and total were 240 U, 300 U and 360 U, respectively. BoNT-A
(OnabotulinumtoxinA) was diluted with saline to a concentration of 25 U/mL. A team consisting of two
physicians, an occupational therapist and a nurse observed the degree of upper and lower limb paresis,
the degree of muscle contraction, the extent of dysfunction due to paresis and spasticity and the affected
ADL. On the basis of these observations, the team planned the sites and dosage of BoNT-A injection by
estimating the possibility of upper and lower limb functional improvement due to the reduction of
muscle contraction. All patients were injected by the same physician. Ultrasonography was used to
guide BoNT-A injections for all muscles. As the effects of BoNT-A are dose-dependent, we determined
the dosages according to previous studies, the degree of spasticity and clinical experience, within the
range of maximum dosages mentioned above [7–9].
5.4. Motor Function Evaluation
With regard to the MAS, we assessed the shoulder, elbow, wrist, finger, knee and ankle. The MAS
was shown to have high reliability as a tool for measuring spasticity [33]. The degree of spasticity
is classified into a total of 6 stages: 0, no increase in muscle tone; 1, Slightly increase in muscle tone,
manifested by a catch and release or by minimal resistance at the end of the range of motion when the
affected parts is moved in flexion or extension; 1+, Slight increase in muscle tone, manifested by a catch,
followed by minimal resistance throughout the remainder (less than half) of the ROM; 2, More marked
increase in muscle tone through most of the ROM but affected parts easily moved; 3, Considerable
increase in muscle tone, passive movement difficult; 4, Affected parts rigid in flexion or extension.
ROM measurements were obtained for hip flexion, knee extension and ankle dorsiflexion (the patient
was resting supine on the examination table with their knees extended). ROM is presented the angular
of the joint and is expressed in degree. In post-stroke patient, the limitation of ROM clinically is caused
by spasticity due to a symptom of upper motor neuron syndrome. The Fugl-Meyer Assessment (FMA)
is a comprehensive assessment battery of motor function that includes assessment of motor function
of the upper and lower limbs [34]. In the upper limb, we used 33 items (maximum points of 66) of the
FMA pertaining to upper limb function, including shoulder, elbow, forearm, wrist and hand. Each
item is rated on a three-point ordinal scale: 0, cannot; 1, can perform partially; 2, can perform fully.
Comfortable gait velocities of the 10 Meter Walk Test (10MWT) were also measured. The patients
walked for 10 m in a straight line, with a 2-m run-up. Time was measured with a stopwatch and
recorded in seconds. The Functional Reach Test (FRT) is used primarily to evaluate the patient fall
risk [35] and reflects static balance [36]. This functional reach is defined as the maximal distance
that one can reach forward beyond arm’s length, while maintaining a fixed base of support in the
standing position.
Clinically, it is considered that FRT values less than 15 cm indicate a high risk of falls.
We conducted this assessment to monitor changes in balance ability due to BoNT-A injections to
both the upper and lower limbs. The Timed Up and Go (TUG) test is associated closely with static
and dynamic balance, walking ability and ADL. It is an easy-to-administer test, yet, it has been shown
to have high reliability [37,38]. In this test, the patients were required to stand up from a chair with
armrests, walk 3 m, turn around, return to the chair and sit down as quickly as possible. Similar to the
10MWT, the time to completion was measured in seconds with a stopwatch. The patients completed
3 trials.
In addition, the use status of a brace, type of the brace and the gait pattern were surveyed during
the protocol treatment. Change in the brace used were performed as necessary in the rehabilitation
program described below.
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5.5. Rehabilitation Programs
All patients received BoNT-A injections in the afternoon of the day of admission. Beginning on
the following day, the rehabilitation training was administered for 11 consecutive days. Including the
assessment on the day of discharge, the rehabilitation program was a 12-day inpatient protocol.
For the rehabilitation program, we implemented MD-Re. In MD-Re, a team of specialists was
formed consisting of two physicians, a physical therapist, an occupational therapist and nurses.
These members supported the patient and created a rehabilitation program to be shared between
the patient and practitioners, based on the results of the assessment at admission. The team listened
to the patient’s wishes and needs in creating a rehabilitation plan. The rehabilitation goals of each
patient were different, therefore the rehabilitation approach also differed for each patient. Each patient
received rehabilitation personally with a therapist. All patients participated in an individually tailored
goal-oriented rehabilitation program that was developed based on their real-life demands. As the
rehabilitation program aimed to improve not only spasticity but also patient functioning, ADL training,
walking training, balance training, core training and brace adjustment or brace-off training were
included, as well as stretching, positioning and ROM training. Outpatient rehabilitation was not
implemented and the patients were instructed to continue the training regimen provided on the last
day of the self-rehabilitation program at home after discharge.
5.6. Statistical Analyses
Data obtained at hospital discharge of each treatment cycle were compared with those obtained
at the baseline. For the MAS, we converted scores of 1+ into 1.5 upon analysis. Normality was
examined using the Shapiro-Wilk test. The data were analyzed by an analysis of variance with
repeated measurements if they were normally distributed and data were analyzed by Friedman
test if they were not normally distributed. In addition, patients were classified into three groups
(“not wearing brace” group, “brace-off” group and “brace-on” group) according to their status of the
use of a brace. These data were analyzed comparatively among the groups.
Bonferroni corrections were used for multiple comparisons. All analyses were performed using
SPSS 21.0 software (IBM, Armonk, NY, USA). A p-value < 0.05 indicated statistical significance in
all tests.
Author Contributions: All authors conceived and designed the experiments; T.H., H.H. and Y.S. performed the
experiments; T.H. and Y.S. analyzed the data; T.H. wrote the paper.
Funding: This research received no external funding.
Conflicts of Interest: The authors declare no conflict of interest.
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